Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.82)
# 470
Out of 4,649 analysts
398
Total ratings
51.8%
Success rate
19.8%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintained: Buy | $332 | $294.60 | +12.70% | 9 | Aug 14, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $40 | $12.94 | +209.12% | 12 | Aug 14, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $34.88 | $9.31 | +274.67% | 4 | Aug 12, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $56 → $70 | $68.57 | +2.09% | 11 | Aug 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $30 | $18.46 | +62.51% | 25 | Aug 7, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $90 | $54.51 | +65.11% | 9 | Aug 7, 2026 | |
| EOLS Evolus | Reiterated: Buy | $17 | $8.16 | +108.46% | 27 | Aug 6, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $230 → $275 | $244.96 | +12.26% | 42 | Aug 4, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | $95 | $33.19 | +186.23% | 25 | Jul 30, 2026 | |
| IVA Inventiva | Reiterated: Buy | $15 | $4.60 | +226.09% | 18 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $14.75 | +171.19% | 1 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $10.77 | +290.15% | 26 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $156.13 | +60.12% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $25.64 | +102.81% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $55 | $48.27 | +13.94% | 31 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $9.58 | +192.28% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.94 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.7961 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2,169.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.90 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $7.05 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.93 → $19.53 | $9.02 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.007524 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $3.09 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $2.07 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $13.04 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $7.41 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $114.47 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $8.23 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $34.42 | n/a | 1 | Oct 18, 2011 |
Ligand Pharmaceuticals
Aug 14, 2026
Maintained: Buy
Price Target: $332
Current: $294.60
Upside: +12.70%
Oculis Holding AG
Aug 14, 2026
Maintained: Buy
Price Target: $40
Current: $12.94
Upside: +209.12%
Eupraxia Pharmaceuticals Inc.
Aug 12, 2026
Reiterated: Buy
Price Target: $34.88
Current: $9.31
Upside: +274.67%
MBX Biosciences
Aug 11, 2026
Maintained: Buy
Price Target: $56 → $70
Current: $68.57
Upside: +2.09%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $18.46
Upside: +62.51%
Structure Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $90
Current: $54.51
Upside: +65.11%
Evolus
Aug 6, 2026
Reiterated: Buy
Price Target: $17
Current: $8.16
Upside: +108.46%
Jazz Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $230 → $275
Current: $244.96
Upside: +12.26%
Viking Therapeutics
Jul 30, 2026
Maintained: Buy
Price Target: $95
Current: $33.19
Upside: +186.23%
Inventiva
Jul 20, 2026
Reiterated: Buy
Price Target: $15
Current: $4.60
Upside: +226.09%
Jul 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $14.75
Upside: +171.19%
Jun 25, 2026
Reiterated: Buy
Price Target: $42
Current: $10.77
Upside: +290.15%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $156.13
Upside: +60.12%
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $25.64
Upside: +102.81%
May 6, 2026
Maintained: Hold
Price Target: $55
Current: $48.27
Upside: +13.94%
Jan 15, 2026
Maintained: Buy
Price Target: $28
Current: $9.58
Upside: +192.28%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.94
Upside: -
Apr 1, 2025
Maintained: Buy
Price Target: $8
Current: $0.7961
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: n/a
Current: $2,169.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.90
Upside: n/a
Aug 30, 2023
Maintained: Hold
Price Target: $11
Current: $7.05
Upside: n/a
Nov 3, 2022
Maintained: Buy
Price Target: $20.93 → $19.53
Current: $9.02
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.007524
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $3.09
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $5
Current: $2.07
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $13.04
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $7.41
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $114.47
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $8.23
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $34.42
Upside: n/a